GleamWall
中文EN

BNR Burning Rock Biotech Ltd Annual reports only

Services-Medical Laboratories · Nasdaq · SEC CIK 1792267

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-4.0%
TTM net income YoY47.0%
TTM EPS YoY—
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—

Margins

Gross margin70.3%
Operating margin-69.3%
Net margin-67.2%
FCF margin-18.9%
EBITDA margin-59.2%

Returns

ROE-51.4%
ROA-36.0%
ROIC (approx.)-263.6%
Asset turnover0.54x

Leverage & solvency

Liabilities / assets34.4%
Debt / equity0.00x
Current ratio2.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.27x
Accruals ratio-26.4%
Payout ratio—
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31 · USDFY20242024-12-31 · CNY
Income statement
Revenue$77.16M515.82M
Cost of revenue$19.54M153.42M
Gross profit$57.62M362.40M
R&D expense$23.81M232.29M
SG&A expense$18.03M261.64M
Operating income-$7.84M-357.56M
Pretax income-$7.69M-340.74M
Income tax$223,0005.88M
Net income-$7.92M-346.63M
EBITDA-$4.73M-305.36M
EPS (diluted)——
Banking
Net interest income-$4,0000
Balance sheet
Cash & equivalents$68.41M519.85M
Receivables$24.25M152.01M
Inventory$6.95M53.76M
Current assets$105.62M776.62M
PP&E, net$4.45M47.15M
Intangibles$41,000421,000
Total assets$117.31M885.30M
Current liabilities$35.32M266.30M
Long-term debt$243,0000
Total debt$243,0000
Total liabilities$40.77M304.48M
Shareholders' equity$76.54M580.83M
Net debt-$68.17M-519.85M
Cash flow statement
Operating cash flow-$4.07M-92.26M
Capital expenditure$751,0005.42M
Free cash flow-$4.82M-97.68M
Investing cash flow-$628,000-4.41M
Financing cash flow$272,000-72,000
Depreciation & amortization$3.11M52.20M
Stock-based compensation$1.98M155.62M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.